Filing Letter - VARIZIG, November 8, 2012

Our Reference: STN 125430/0

Cangene Corporation
Attention: Mr. Terry Kraynyk
November 8, 2012
Sent by email

Dear Mr. Kryanyk:

We are reviewing your biologics license application for Varicella Zoster Immune Globulin (Human) submitted on June 29, 2012 for post exposure prophylaxis of varicella in high-risk individuals. We have the following request for information:

1. Study VZ-006 did not show a statistically significant difference in performance of VariZIG and VZIG. Based on this result you wrote:


“In summary, VariZIG was shown to be well-tolerated and with an efficacy profile comparable to that of licensed VZIG, in preventing or modifying the course of varicella infection in pregnant women without immunity to VZV.” (2.7.6 Synopses of Individual Studies, page 9)

Please provide a precise statistical hypothesis tested in this study that can explain the term “comparable.”

Please submit your response to this information request as an amendment to this file by November 15, 2012 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.


If you have any questions, please contact me at (301) 827-6174.


Sincerely,


Nannette Cagungun, MS, PD, RAC 
Regulatory Project Manager 
OBRR/CBER/FDA, HFM-380 
1401 Rockville Pike Rockville, MD 20852-1448 
Tel: (301) 827 6174 
Fax: (301) 827 2857


THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.
